Data-quality flags on Tanzania
% of people on ART who are virally suppressed (third 95), Dodoma, 2018 (PEPFAR results by province). The ratio of 17,247 people reported as virally suppressed to a denominator of 16,660 is 103.5 per cent, above 100 per cent, so the numerator and the denominator do not come from the same group of patients for Dodoma in 2018.
% of people on ART who are virally suppressed (third 95), Singida, 2018 (PEPFAR results by province). The ratio of 9,844 people reported as virally suppressed to a denominator of 9,012 is 109.2 per cent, above 100 per cent, so the numerator and the denominator do not come from the same group of patients for Singida in 2018.
People receiving PrEP, 2021 (PEPFAR Panorama Spotlight). The value moved from 7,147 in 2020 to 33,773 in 2021, a change of more than threefold in a single year. The move from 7,147 to 33,773 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2020 and 2021 are not comparable. Check the figures by reporting organisation before reading a trend across 2020 and 2021.
People who completed a course of TB preventive therapy, 2019 (PEPFAR Panorama Spotlight). The value moved from 58,528 in 2018 to 401,595 in 2019, a change of more than threefold in a single year. The move from 58,528 to 401,595 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2018 and 2019 are not comparable. Check the figures by reporting organisation before reading a trend across 2018 and 2019.
Sources of the figures for Tanzania
| Source | Type | Rows | Indicators | Years | Read from | Retrieved |
|---|---|---|---|---|---|---|
| PEPFAR results by province | Programme record | 1,928 | 7 | 2016–2025 | data.pepfar.gov | 2026-10-12 |
| UNICEF HIV/AIDS dataset | Modelled estimate | 1,376 | 5 | 2010–2025 | sdmx.data.unicef.org | 2026-10-20 |
| UNAIDS HIV sub-national estimates viewer (Naomi) | Modelled estimate | 1,344 | 7 | 2022–2025 | nmviewerserver.azurewebsites.net | 2026-10-14 |
| PEPFAR results by funding agency and province | Programme record | 1,032 | 9 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| UNAIDS AIDSinfo | Modelled estimate | 824 | 30 | 2000–2024 | aidsinfo.unaids.org | 2026-10-20 |
| Demographic and Health Surveys | Survey | 529 | 4 | 2003–2022 | api.dhsprogram.com | 2026-10-16 |
| WHO Global Health Observatory | Modelled estimate | 267 | 12 | 2000–2025 | ghoapi.azureedge.net | 2026-10-12 |
| WHO Global Tuberculosis Programme | Programme record | 182 | 17 | 2000–2025 | extranet.who.int | 2026-10-16 |
| ForeignAssistance.gov | Expenditure account | 119 | 5 | 2001–2026 | foreignassistance.gov | 2026-10-29 |
| PEPFAR Panorama Spotlight | Programme record | 87 | 11 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR results by funding agency | Programme record | 72 | 9 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| OECD Creditor Reporting System | Expenditure account | 68 | 3 | 2002–2024 | sdmx.oecd.org | 2026-10-12 |
| IATI, through d-portal | Expenditure account | 66 | 3 | 2000–2026 | d-portal.org | 2026-10-12 |
| Global Fund Data Service | Programme record | 57 | 11 | 2017–2025 | fetch.theglobalfund.org | 2026-10-12 |
| World Bank Open Data | Modelled estimate | 51 | 2 | 2000–2025 | api.worldbank.org | 2026-10-12 |
| PEPFAR testing by modality | Programme record | 48 | 6 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| WHO HIV testing services dashboard | Programme record | 47 | 5 | 2018–2024 | eic-database-290813.ew.r.appspot.com | 2026-10-14 |
| UNAIDS Global AIDS Monitoring expenditure database | Expenditure account | 42 | 10 | 2016–2020 | hivfinancial.unaids.org | 2026-10-12 |
| WHO Global Health Expenditure Database | Expenditure account | 42 | 7 | 2014–2019 | apps.who.int | 2026-10-12 |
| PEPFAR budgets and expenditure | Expenditure account | 40 | 8 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR commodity procurement plans | Expenditure account | 28 | 4 | 2019–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR operating-unit budgets | Expenditure account | 19 | 2 | 2005–2020 | data.pepfar.gov | 2026-10-12 |
| UNAIDS Data 2025 country databook | Expenditure account | 15 | 3 | 2016–2020 | aidsinfo.unaids.org | 2026-10-15 |
| Population-based HIV Impact Assessment (PHIA) surveys, through the UNAIDS Inequalities dashboard | Survey | 12 | 4 | 2017 | aidsinfo.unaids.org | 2026-10-15 |
| PEPFAR voluntary medical male circumcision | Programme record | 8 | 1 | 2010–2017 | data.pepfar.gov | 2026-10-12 |
| Global Fund allocations | Expenditure account | 4 | 1 | 2017–2026 | fetch.theglobalfund.org | 2026-10-12 |
| PEPFAR human resources for health inventory | Expenditure account | 3 | 3 | 2025 | data.pepfar.gov | 2026-10-12 |
Indicators held
| Indicator | Domain | Unit | Rows | Years | Sources | Most recent value |
|---|---|---|---|---|---|---|
| Actual expenditure on collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $405k (2024) |
| Budget required for collaborative TB/HIV activities | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $4.3m (2025) |
| Country-reported HIV expenditure, all sources | Financing | USD | 10 | 2016–2020 | UNAIDS AIDSinfo, UNAIDS Global AIDS Monitoring expenditure database | $558.0m (2020) |
| Domestic funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $9.2m (2024) |
| Domestic public HIV expenditure | Financing | USD | 10 | 2016–2020 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $5.3m (2020) |
| Expected Global Fund funding for the national TB programme | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $20.8m (2025) |
| Expected USAID funding for the national TB programme | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $8.0m (2025) |
| Expected domestic funding for the national TB programme | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $16.8m (2025) |
| Expected funding for collaborative TB/HIV activities | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $43k (2025) |
| External HIV and STD spending, national health accounts | Financing | USD | 6 | 2014–2019 | WHO Global Health Expenditure Database | $528.9m (2019) |
| External HIV financing (all donors, ODA) | Financing | USD | 23 | 2002–2024 | OECD Creditor Reporting System | $440.2m (2024) |
| External HIV financing from governments other than the United States (IATI) | Financing | USD | 27 | 2000–2026 | IATI, through d-portal | $581k (2026) |
| External HIV financing from multilateral bodies other than the Global Fund (IATI) | Financing | USD | 15 | 2012–2026 | IATI, through d-portal | $909k (2026) |
| External HIV financing from the United States (ODA) | Financing | USD | 49 | 2001–2026 | ForeignAssistance.gov, OECD Creditor Reporting System | $116.4m (2026) |
| Funding received for collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $405k (2024) |
| Global Fund HIV allocation for a whole three-year cycle, not an annual figure | Financing | USD per three-year allocation cycle | 4 | 2017–2026 | Global Fund allocations | 335,619,792 (2026) |
| Global Fund HIV disbursements to the country | Financing | USD | 46 | 2003–2026 | IATI, through d-portal, OECD Creditor Reporting System | $25.5m (2026) |
| Global Fund funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $24.4m (2024) |
| Government HIV and STD spending as a share of government health spending | Financing | percent | 6 | 2014–2019 | WHO Global Health Expenditure Database | 9.7% (2019) |
| Government HIV and STD spending, national health accounts | Financing | USD | 6 | 2014–2019 | WHO Global Health Expenditure Database | $92.7m (2019) |
| HIV and STD spending as a share of all external health spending | Financing | percent | 6 | 2014–2019 | WHO Global Health Expenditure Database | 60.7% (2019) |
| HIV and STD spending as a share of all health spending | Financing | percent | 6 | 2014–2019 | WHO Global Health Expenditure Database | 29.9% (2019) |
| HIV and STD spending, national health accounts | Financing | USD | 6 | 2014–2019 | WHO Global Health Expenditure Database | $706.3m (2019) |
| HIV spending on critical enablers | Financing | USD | 4 | 2017–2020 | UNAIDS Global AIDS Monitoring expenditure database | $6.8m (2020) |
| HIV spending on governance and sustainability | Financing | USD | 3 | 2016–2018 | UNAIDS Global AIDS Monitoring expenditure database | $13.5m (2018) |
| HIV spending on prevention | Financing | USD | 5 | 2016–2020 | UNAIDS Global AIDS Monitoring expenditure database | $108.6m (2020) |
| HIV spending on programmes for children and adolescents | Financing | USD | 3 | 2016–2020 | UNAIDS Global AIDS Monitoring expenditure database | $16.1m (2020) |
| HIV spending on social protection and economic support | Financing | USD | 2 | 2019–2020 | UNAIDS Global AIDS Monitoring expenditure database | $4.2m (2020) |
| HIV spending on treatment, care and support | Financing | USD | 5 | 2016–2020 | UNAIDS Global AIDS Monitoring expenditure database | $286.7m (2020) |
| International HIV expenditure (country-reported) | Financing | USD | 10 | 2016–2020 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $551.1m (2020) |
| PEPFAR expenditure, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $132.4m (2025) |
| PEPFAR expenditure, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $127.4m (2025) |
| PEPFAR expenditure, all US agencies | Financing | USD | 8 | 2018–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets | $290.3m (2025) |
| PEPFAR expenditure, other US agencies | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $30.5m (2025) |
| PEPFAR planned commodity procurement, like for like | Financing | USD | 7 | 2019–2025 | PEPFAR commodity procurement plans | $57.5m (2025) |
| PEPFAR planned funding (budget), all US agencies | Financing | USD | 21 | 2005–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets | $380.0m (2025) |
| PEPFAR planned funding, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $150.7m (2025) |
| PEPFAR planned funding, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $182.5m (2025) |
| PEPFAR planned funding, other US agencies | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $46.8m (2025) |
| PEPFAR planned procurement of antiretroviral drugs | Financing | USD | 7 | 2019–2025 | PEPFAR commodity procurement plans | $28.2m (2025) |
| PEPFAR planned procurement of laboratory commodities | Financing | USD | 7 | 2019–2025 | PEPFAR commodity procurement plans | $18.5m (2025) |
| PEPFAR planned procurement of rapid test kits | Financing | USD | 7 | 2019–2025 | PEPFAR commodity procurement plans | $236k (2025) |
| PEPFAR spend on staff, human resources for health inventory | Financing | USD | 1 | 2025 | PEPFAR human resources for health inventory | $135.4m (2025) |
| PEPFAR-funded staff delivering services, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 24,556 (2025) |
| PEPFAR-funded staff, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 30,489 (2025) |
| Private HIV and STD spending, national health accounts | Financing | USD | 6 | 2014–2019 | WHO Global Health Expenditure Database | $84.7m (2019) |
| Private HIV expenditure (country-reported) | Financing | USD | 10 | 2016–2020 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $1.6m (2020) |
| US HIV disbursements managed by Health and Human Services | Financing | USD | 24 | 2003–2026 | ForeignAssistance.gov | $37.0m (2026) |
| US HIV disbursements managed by USAID | Financing | USD | 26 | 2001–2026 | ForeignAssistance.gov | $20k (2026) |
| US HIV disbursements managed by other US agencies | Financing | USD | 25 | 2002–2026 | ForeignAssistance.gov | $210k (2026) |
| US HIV disbursements managed by the State Department | Financing | USD | 18 | 2008–2026 | ForeignAssistance.gov | $79.1m (2026) |
| USAID funding received by the national TB programme | Financing | USD | 7 | 2018–2024 | WHO Global Tuberculosis Programme | $8.0m (2024) |
| % of ALL PLHIV who are virally suppressed | Treatment cascade | percent | 17 | 2017–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 85.0% (2025) |
| % of PLHIV on ART (second 95, PLHIV base) | Treatment cascade | percent | 259 | 2000–2025 | UNAIDS AIDSinfo, UNAIDS HIV sub-national estimates viewer (Naomi), WHO Global Health Observatory | 89.0% (2025) |
| % of PLHIV who have been diagnosed (first 95) | Treatment cascade | percent | 220 | 2010–2025 | UNAIDS AIDSinfo, UNAIDS HIV sub-national estimates viewer (Naomi), WHO Global Health Observatory | 92.0% (2025) |
| % of estimated HIV-positive incident TB cases on TB treatment and ART | Treatment cascade | percent | 21 | 2002–2024 | UNAIDS AIDSinfo | 63.5% (2024) |
| % of people currently enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 4 | 2018–2023 | UNAIDS AIDSinfo | 11.0% (2023) |
| % of people living with HIV on ART (household survey) | Treatment cascade | percent | 3 | 2017 | Population-based HIV Impact Assessment (PHIA) surveys, through the UNAIDS Inequalities dashboard | By population group, sex or age only, to 2017 |
| % of people living with HIV on ART who completed a course of TB preventive therapy | Treatment cascade | percent | 3 | 2022–2024 | UNAIDS AIDSinfo | 83.0% (2024) |
| % of people living with HIV who are virally suppressed (household survey) | Treatment cascade | percent | 3 | 2017 | Population-based HIV Impact Assessment (PHIA) surveys, through the UNAIDS Inequalities dashboard | By population group, sex or age only, to 2017 |
| % of people newly enrolled in HIV treatment diagnosed with TB disease | Treatment cascade | percent | 5 | 2014–2024 | UNAIDS AIDSinfo | 6.9% (2024) |
| % of people newly enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 7 | 2013–2024 | UNAIDS AIDSinfo | 6.9% (2024) |
| % of people on ART who are virally suppressed (third 95) | Treatment cascade | percent | 280 | 2017–2025 | PEPFAR results by province, WHO Global Health Observatory | 97.0% (2025) |
| % of returned HIV test results that were positive | Treatment cascade | percent | 31 | 2018–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 1.2% (2024) |
| HIV self-test kits distributed | Treatment cascade | count | 4 | 2020–2024 | WHO HIV testing services dashboard | 899,843 (2024) |
| HIV tests performed at a health facility | Treatment cascade | count | 14 | 2018–2025 | PEPFAR testing by modality, WHO HIV testing services dashboard | 1,623,236 (2025) |
| HIV tests performed through community outreach | Treatment cascade | count | 13 | 2018–2025 | PEPFAR testing by modality, WHO HIV testing services dashboard | 343,945 (2025) |
| HIV tests performed with the result returned to the person | Treatment cascade | count | 359 | 2016–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 1,967,181 (2025) |
| HIV-exposed infants tested within two months of birth | Treatment cascade | percent | 15 | 2010–2024 | UNAIDS AIDSinfo | 72.0% (2024) |
| HIV-positive TB patients started or continued on ART | Treatment cascade | count | 24 | 2015–2025 | Global Fund Data Service, WHO Global Tuberculosis Programme | 12,171 (2025) |
| Key-population people tested for HIV (count over the period) | Treatment cascade | count | 2 | 2024–2025 | Global Fund Data Service | By population group, sex or age only, to 2025 |
| Newly diagnosed at HHS/CDC-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 150 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 14,158 (2025) |
| Newly diagnosed at USAID-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 205 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 12,481 (2025) |
| Newly diagnosed at other US-agency partners (MER HTS_TST_POS) | Treatment cascade | count | 42 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 3,627 (2025) |
| Newly enrolled on ART at HHS/CDC-funded partners (MER TX_NEW) | Treatment cascade | count | 129 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 14,189 (2025) |
| Newly enrolled on ART at USAID-funded partners (MER TX_NEW) | Treatment cascade | count | 183 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 10,702 (2025) |
| Newly enrolled on ART at other US-agency partners (MER TX_NEW) | Treatment cascade | count | 42 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 3,690 (2025) |
| Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS) | Treatment cascade | count | 324 | 2016–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality | 30,266 (2025) |
| Number of PLHIV virally suppressed (VL<1000) | Treatment cascade | count | 279 | 2017–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province | 1,362,495 (2025) |
| Number of people on ART (PEPFAR MER TX_CURR) | Treatment cascade | count | 581 | 2000–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, UNAIDS AIDSinfo, UNAIDS HIV sub-national estimates viewer (Naomi), WHO Global Health Observatory, WHO Global Tuberculosis Programme | 1,561,945 (2025) |
| PMTCT ART coverage among pregnant women with HIV | Treatment cascade | percent | 31 | 2010–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset | 95.0% (2025) |
| People living with HIV in care screened for TB | Treatment cascade | count | 4 | 2017–2020 | Global Fund Data Service | 2,305,830 (2020) |
| People living with HIV on ART who started TB preventive therapy | Treatment cascade | count | 7 | 2018–2025 | Global Fund Data Service | 98,877 (2025) |
| People newly diagnosed at a health facility | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 20,209 (2025) |
| People newly diagnosed through community outreach | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 10,057 (2025) |
| People newly enrolled on ART during the year | Treatment cascade | count | 320 | 2014–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, WHO Global Tuberculosis Programme | 28,581 (2025) |
| People on ART at HHS/CDC-funded partners (MER TX_CURR) | Treatment cascade | count | 128 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 819,781 (2025) |
| People on ART at USAID-funded partners (MER TX_CURR) | Treatment cascade | count | 183 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 488,231 (2025) |
| People on ART at other US-agency partners (MER TX_CURR) | Treatment cascade | count | 42 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 226,792 (2025) |
| People tested for HIV in the last 12 months who received the result (household survey) | Treatment cascade | percent | 138 | 2003–2022 | Demographic and Health Surveys | By population group, sex or age only, to 2022 |
| People who completed a course of TB preventive therapy | Treatment cascade | count | 8 | 2018–2025 | PEPFAR Panorama Spotlight | 52,319 (2025) |
| Pregnant women tested for HIV in antenatal care | Treatment cascade | percent | 9 | 2015–2024 | UNAIDS AIDSinfo | 93.0% (2024) |
| Pregnant women with HIV who received ARVs for PMTCT | Treatment cascade | count | 48 | 2010–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, UNAIDS AIDSinfo, WHO Global Health Observatory | 67,520 (2025) |
| TB patients recorded as HIV-positive | Treatment cascade | count | 23 | 2015–2025 | PEPFAR Panorama Spotlight, WHO Global Tuberculosis Programme | 3,102 (2025) |
| TB patients with an HIV test result recorded | Treatment cascade | count | 26 | 2015–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, WHO Global Tuberculosis Programme | 14,900 (2025) |
| AIDS-related deaths | Epidemic estimates | count | 681 | 2000–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 23,000 (2025) |
| Deaths from TB among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 6,500 (2024) |
| HIV incidence per 1,000 uninfected people a year (household survey) | Epidemic estimates | per_1000 | 3 | 2017 | Population-based HIV Impact Assessment (PHIA) surveys, through the UNAIDS Inequalities dashboard | By population group, sex or age only, to 2017 |
| HIV prevalence among a key population | Epidemic estimates | percent | 4 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| HIV prevalence, ages 15-49 | Epidemic estimates | percent | 368 | 2000–2025 | Demographic and Health Surveys, Population-based HIV Impact Assessment (PHIA) surveys, through the UNAIDS Inequalities dashboard, UNAIDS AIDSinfo, UNAIDS HIV sub-national estimates viewer (Naomi), World Bank Open Data | 3.4% (2025) |
| Incident TB cases among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 19,000 (2024) |
| New HIV infections | Epidemic estimates | count | 777 | 2000–2025 | UNAIDS AIDSinfo, UNAIDS HIV sub-national estimates viewer (Naomi), UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 34,000 (2025) |
| People living with HIV | Epidemic estimates | count | 873 | 2000–2025 | UNAIDS AIDSinfo, UNAIDS HIV sub-national estimates viewer (Naomi), UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 1,800,000 (2025) |
| Condom use at last higher-risk sex (household survey) | Prevention and outreach | percent | 138 | 2003–2022 | Demographic and Health Surveys | By population group, sex or age only, to 2022 |
| Key-population members reached by prevention programmes | Prevention and outreach | percent | 1 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Key-population people reached by outreach (count over the period) | Prevention and outreach | count | 2 | 2024–2025 | Global Fund Data Service | By population group, sex or age only, to 2025 |
| Male condoms distributed in a year | Prevention and outreach | count | 5 | 2019–2024 | UNAIDS AIDSinfo | 109,155,900 (2024) |
| People receiving PrEP | Prevention and outreach | count | 181 | 2017–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province, UNAIDS AIDSinfo | 47,140 (2025) |
| People with comprehensive correct knowledge of HIV (household survey) | Prevention and outreach | percent | 130 | 2003–2022 | Demographic and Health Surveys | By population group, sex or age only, to 2022 |
| Voluntary medical male circumcisions performed | Prevention and outreach | count | 32 | 2008–2024 | PEPFAR Panorama Spotlight, PEPFAR voluntary medical male circumcision, UNAIDS AIDSinfo | 815,602 (2024) |
| Estimated pregnant women with HIV needing ARVs for PMTCT | Population denominators | count | 31 | 2010–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 69,000 (2025) |
| Estimated size of a key population | Population denominators | count | 3 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Total population | Population denominators | count | 218 | 2000–2025 | UNAIDS HIV sub-national estimates viewer (Naomi), World Bank Open Data | 70,545,865 (2025) |
| Share of HIV-exposed infants who acquire HIV | — | percent | 31 | 2010–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset | 6.9% (2025) |
Every row shown on the Tanzania page is in the panel download, with the source URL and the retrieval date of the row attached. See Data.
Turn your phone to read the chart upright